GSK GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact of COVID-19, spun off its consumer healthcare arm and returned to revenue growth. GSK country managers PharmaBoardroom has interviewed over…
Takeda Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC and consumer goods. Here, four country and regional managers that PharmaBoardroom has spoken to in the past 12 months discuss…
Greece After 15 years of economic struggles coupled with political swings to the left and right, Greece seems to be on its surest footing in decades. Indeed, the Economist observed that the May 2023 election victory of incumbent Greek Prime Minister Kyriakos Mitsotakis (and the heavy defeat handed to his left…
Greece Country managers from three leading medtech multinationals give their take on the key access challenges facing medical device companies in Greece. New Access Models “While some value-based procurement agreements have been struck in the private sector, we are struggling to gain acceptance for such agreements in the public sector.…
Greece One of Greece’s leading domestic pharmaceutical companies, RAFARM has had a stellar recent history, including a momentous entry into the US market. Now looking to establish itself as one of Europe’s major players in ophthalmics and complex injectables, VP Aris Mitsopoulos highlights the key learnings from this US experience and…
Greece Greece is a middling performer in terms of clinical trial numbers on the European stage, nestled next to Finland and Romania on total trial numbers between 2002 and 2020 but ahead of Germany and Italy on trials per capita. However, the pharmaceutical industry does see opportunities for establishing greater trial…
Greece Greece’s deep and painful sovereign debt crisis lasted almost a decade and saw up to 500,000 Greeks leave the country in search of opportunities elsewhere as the country’s economy shrunk by a quarter and unemployment shot up to 28 percent. 26 percent of those emigrating held a degree, and 69…
Greece The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic and social impact of the COVID-19 pandemic, but for many biopharma industry leaders they also present an opportunity to tackle…
Greece DEMO, founded in 1965, is a mainstay of Greek pharma and one of its largest companies, accounting for 25 percent of the total investment across the entire Greek pharmaceutical sector. Throughout its long history DEMO has shifted its focus, moved towards exports and weathered Greece’s financial crisis. Today, the family-owned…
Greece The European Union’s decision to mitigate the effects of the COVID-19 pandemic by launching its Recovery and Resilience Facility (RRF) and moving away from its past austerity policies is particularly significant for Greece. Severely hit by the financial crisis a decade ago and thrown off its course to recovery by…
Greece In Greece, both innovators and the generics industry find fault with the country’s rebates and clawbacks system, a hold over cost-containment measure from the country’s period of extreme economic turmoil. In conversation with PharmaBoardroom, Michael Himonas, GM of the Hellenic Association of Pharmaceutical Companies (SFEE) and Faye Kosmopolou, GM of…
Greece Pharmaceutical logistics companies in Greece have had to work hard and innovatively to emerge from the debt crisis; focusing on leveraging international connections and maintaining quality to stay profitable. Now however, major new international investment into the port of Piraeus stands to put Greece back on the world logistics map.…
See our Cookie Privacy Policy Here